Biomarkers/CVD Do Cardiac biomarkers or tests add value to CVD risk prediction?

There are multiple biomarkers available in research settings and clinical practice. Measurement of biomarkers can be important to determine cause, aetiology and prognosis in many diseases. In CVD risk prediction, accurate estimation of risk is essential in order to targeting interventions at those who would most benefit. The place of biomarkers is in improving accuracy of risk prediction. Biomarkers can be useful to predict development of CVD but will not necessarily explain the mechanism of disease. ‘Risk prediction tools are just tool’, said Professor Arno Hoes (Utrecht, Netherlands). The plethora of biomarkers which have come to market in recent years have shown disappointing results overall in terms of improvement in risk prediction. ‘Evidence of CRP in predicting CVD risk is not good enough to justify doing the test in everyday practice’ said Professor Hoes.

‘Cardiovascular risk profiling is becoming increasingly important and better tools are needed to allow clinicians to identify which patients should receive preventative therapies. Accurate prediction is the essence of risk scoring’.




 

---

View presentation